PIN1 and breast carcinoma: Fifth, PIN1 knockdown or pharmacological inhibition sensitizes cancer cells of different origins to chemo- and target therapy, such as breast cancers to 5-fluorouracil, Taxol (151), and rapamycin (171), hepatocellular carcinoma to sorafenib (172), colon cancer to Taxol (72) and acute myeloid leukemia to retinoic acid (173).